linjc16/ctgov huggingface dataset:
Retrospective Treatment Pattern Survey for the Patients With Hypertension and Stroke

Study Overview
=================
Brief Summary
-----------------
This study will address the treatment rate and control rate of hypertension, treatment pattern and factors that affect BP control by examining retrospective medical records of hypertension patients recovering from stroke, among outpatients coming to the Neurology Department in 10 university hospitals nationwide.

Official Title
-----------------
A Retrospective, Multi Centre, Non-Interventional, Observational Study to Investigate Treatment Pattern of Blood Pressure in the Post Stroke Patients With Hypertension.

Conditions
-----------------
Hypertension

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients had been hospitalized as a acute stroke in 2006 Patient with history of stroke receiving hypertension medication during at least 1 year. Exclusion Criteria: Secondary hypertension patients Patients not receiving hypertension medication

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Hypertension patients recovering from stroke | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Attainment rate to the target blood pressure |  | After collecting all Patient Record Form. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dropout rate will be estimated during the follow-up period after the hypertension treatment. Attainment to the target blood pressure will be investigated according to concomitant diseases. |  | After collecting all Patient Record Form. | 
| Change in DBP/SBP value during the follow-up period will be addressed. Change in the DBP/SBP value will be investigated according to the risk factors and concurrent disease. |  | After collecting all Patient Record Form. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypertension, Post stroke, JNC7, 2007 ESH-ESC guidelines, survey
Genetic Basis of Pacing-induced Cardiomyopathy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to collect a saliva sample from patients with a pacemaker to study genes involved in cardiomyopathy, a condition where the heart muscle is abnormal.

Detailed Description
-----------------
DNA will be extracted from the saliva to test for changes in genes related to cardiomyopathy.

Official Title
-----------------
Genetic Basis of Pacing-Induced Cardiomyopathy

Conditions
-----------------
Pacemaker, Artificial, Cardiomyopathies

Intervention / Treatment
-----------------
* Other: Saliva sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who have been assessed for cardiomyopathy Exclusion Criteria: Patients who do not have adequate follow up care to determine if they do or do not have cardiomyopathy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Saliva - cardiomyopathy<br>Saliva sample for genetic testing from subjects who developed cardiomyopathy | Other: Saliva sample<br>* Extract sample of saliva only once<br>|
| Saliva - no cardiomyopathy<br>Saliva sample for genetic testing from subjects who do not have cariomyopathy | Other: Saliva sample<br>* Extract sample of saliva only once<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with genotype frequency | Number of participants with genotype frequency based on genetic testing of saliva samples | through study completion, an average of 1 year |
Pilot Trial of a System for Motor Function Recovery

Study Overview
=================
Brief Summary
-----------------
This is a multi-center, prospective, blinded, pilot feasibility study to evaluate improvement in sensory and motor function with sham.

Official Title
-----------------
Pilot Feasibility Clinical Validation Study

Conditions
-----------------
Spinal Cord Diseases

Intervention / Treatment
-----------------
* Device: Stimulator
* Device: Sham


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Traumatic chronic spinal cord injury Exclusion Criteria: Active implanted medical device Internal metallic objects of unknown or foreign origin Implanted anti-spasticity pumps, Botox injections in prior 3 months or other current anti-spasticity regimen BMI > 40.0 Acute medical conditions under active treatment that would contraindicate standard rehabilitation including open wounds Pregnancy or planned pregnancy Unhealed bone fractures, peripheral neuropathies or painful musculoskeletal dysfunction Cardiopulmonary disease or ventilator dependency Uncontrolled epilepsy or seizures Clinically significant depression, psychiatric disorders or ongoing substance abuse

Ages Eligible for Study
-----------------
Minimum Age: 22 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Neuromodulation<br>Neuromodulation | Device: Stimulator<br>* Neuromodulation<br>|
| Sham Comparator: Sham<br>Sham | Device: Sham<br>* Sham<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Graded Redefined Assessment of Strength, Sensibility and Prehension (GRASSP) | Change in Graded Redefined Assessment of Strength, Sensibility and Prehension (GRASSP) for the upper limbs Scoring: Strength scored 0 - 50 for each arm Sensibility scored 0 - 24 for each arm Prehension scored 0 - 42 for each arm Higher scores are a better outcome | Biweekly through study completion up to 18 weeks |
Pepsinogens as the Early Marker of H. Pylori Eradication

Study Overview
=================
Brief Summary
-----------------
Helicobacter pylori (H. pylori) eradication increases the serum pepsinogen (PG) I/PG II ratio and the percentage change in PG I/PG II ratios was found to be a useful marker of H. pylori eradication (e.g., the PG method). We studied whether the PG method could be an early diagnostic marker of H. pylori eradication even in patients persistently treated with a proton pump inhibitor. Sixty-two H. pylori-positive patients underwent H. pylori-eradication therapy, followed by treatment with a PPI to cure ulcers. Serum levels of PG I and PG II were measured before, at the end of, and at 4 weeks after the eradication therapy. At more than one month after the end of treatments, 13C-urea breath test (UBT) was performed. The cut-off values of percentage changes in PG I/PG II ratios for the diagnosis of eradication of H. pylori were set in proportion to PG I/PG II ratios before eradication in accordance with our previous report. Using the results of UBT as the standard, the percentage change in serum PG I/PG II ratios is useful as an early diagnostic marker for judgment of H. pylori eradication irrespective of PPI treatment.

Official Title
-----------------
Serum Pepsinogens as an Early Diagnostic Marker of H. Pylori Eradication

Conditions
-----------------
H. Pylori Infection, Gastric Ulcer, Duodnal Ulcer

Intervention / Treatment
-----------------
* Procedure: serum pepsinogen
* Procedure: urea breath test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with H. pylori infection Exclusion Criteria: Patients without H. pylori infection

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: serum pepsinogen|nan|
|Procedure: urea breath test|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Whether the serum pepsinogen could be an early diagnostic marker of H. pylori eradication even in patients persistently treated with a proton pump inhibitor compared with 13C-urea breath test. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cost-effectiveness for diagnosis of H. pylori eradication by the serum pepsinogen. |  |  |
Surgical Extrusion: Volumetric and Insertion Analysis at 6 Months.

Study Overview
=================
Brief Summary
-----------------
The aim is to clinically evaluate the changes that occur in teeth that have undergone surgical extrusion treatment. Three parameters will be recorded before and 6 months after treatment: the position and the volume of the soft tissue, and the level of periodontal attachment.

Detailed Description
-----------------
After informing the patient and obtaining his or her consent to surgical extrusion treatment, a model of the pre-treatment situation will be obtained by intraoral scanning and the attachment levels will be recorded by periodontal probing at 6 points around the tooth. The dimensional and positional changes of the soft tissue will be analyzed by superimposing both digital impressions in each patient. In the same way, periodontal attachment levels before and 6 months after treatment will be compared. The data will be analyzed statistically and conclusions will be drawn regarding the surgical extrusion treatment.

Official Title
-----------------
Surgical Extrusion: Volumetric and Insertion Analysis at 6 Months. Series of 10 Cases

Conditions
-----------------
Tooth Extruded, Tooth Extrusion, Tooth Avulsion, Tooth Fracture

Intervention / Treatment
-----------------
* Procedure: Surgical Extrusion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Tooth with a subgingival residual dentine margin. Patients refusing tooth extraction and dental implant placement as first choice. Exclusion Criteria: Patients in whom surgical intervention is contraindicated. Teeth with vertical fractures up to the apex. Teeth with pocket depth >4 mm in any of their walls. Failure of the treatment leading to the loss of the extruded tooth.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Surgical Extrusion<br>Patients who receive surgical extrusion treatment in maxillary premolars. | Procedure: Surgical Extrusion<br>* Relocation of the remaining tooth structure to a more coronal position within the same original socket.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The position of the soft tissue | Measurement of the vertical position of the gingival margin before and 6 months after surgery. | 6 months | 
| The volume changes in the soft tissue | Measurement of vestibular alveolar volume before and 6 months after surgery. | 6 months | 
| The level of insertion | Measurement of the periodontal sulcus before and 6 months after surgery. | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
surgical extrusion, oral surgery, tooth extrusion
Register of Patients With Anti-Phospholipids Syndrome (APS) and/or Systemic Lupus Erythematosus (SLE)

Study Overview
=================
Brief Summary
-----------------
The purpose of that register is to collect medical information about patients suffering of APS with or without associated SLE.

Detailed Description
-----------------
Recruitment of patients with APS and SLE treated. Retrospective and prospective register.

Official Title
-----------------
Register of Patients With Anti-Phospholipids Syndrome (APS) and/or Systemic Lupus Erythematosus (SLE)

Conditions
-----------------
Anti-Phospholipids Syndrome (APS), Systemic Lupus Erythematosus (SLE)

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with APS Patient with SLE Exclusion Criteria: Dependent person Hospitalized without consent and not protected by law Detainee

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients enrolled with Anti-Phospholipids syndrome (APS) and/or Systemic Lupus Erythematosus (SLE) |  | 5 years |
Platelet Products Tested With the ThromboLUX® Platelet Quality Test

Study Overview
=================
Brief Summary
-----------------
The planned minimal risk study is a blinded study on consecutive transfusable platelet products. The aim of the study is to evaluate the quality of platelet components sampled prior to transfusion. The primary patient transfusion outcome in this study is the 1-hour corrected count increment (1 hr CCI), which is a widely accepted clinical outcome measure. Platelet products will be sampled for ThromboLUX testing before being sent from the blood bank to the treatment center. After receipt at the treatment center, the platelet products will be used as per regular clinical practice, and the outcome data from each patient will be collected. At the end of the study, TLX Scores will be compared to the transfusion outcomes to determine if a low TLX Score is associated with a poor transfusion outcome. During the course of the study, the TLX Score will not be known to the clinicians, or utilized in any way to decide if the platelet product should be transfused.

Official Title
-----------------
Blinded Study on Consecutive Transfusable Platelet Products Tested With the ThromboLUX® Platelet Quality Test

Conditions
-----------------
Poor Platelet Transfusion Outcome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult hematology-oncology outpatients stable and thrombocytopenic Exclusion Criteria: age <18 yrs splenomegaly unable to provide informed consent pregnancy acute promyelocytic leukemia ITP (Idiopathic thrombocytopenic purpura) HUS

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Hematology-oncology<br>hematology-oncology outpatients requiring platelet transfusion | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| TLX Score Correlation with CCI | The value of the ThromboLUX Score (obtained from platelet products with the ThromboLUX platelet quality test system) to predict patient transfusion outcome (measured as 1hr corrected count increment CCI). The correlation between ThromboLUX score and 1hr CCI (study endpoint) will be reported at the end of the study | Patients are expected to be enrolled for an average of 6 months. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
platelet, transfusion, ThromboLUX, corrected count increment, thrombocytopenic
NSAIDs in Coronary Artery Disease Patients

Study Overview
=================
Brief Summary
-----------------
Introduction: Different groups already showed in retrospective subgroup analyses, that there is an increased risk for cardiovascular events in patients on a simultaneous ASA/NSAID treatment. Methods: Light-Transmission aggregometry Hypothesis: Simultaneous administration of different NSAIDs and ASA impair the platelet inhibiting effect of ASA.

Official Title
-----------------
Non-steroidal Anti-inflammatory Drugs Impair the Platelet Inhibiting Effect of Acetylsalicylic Acid in Coronary Artery Disease Patients

Conditions
-----------------
CAD

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients on a simultaneous ASA, NSAID treatment > 18 years Exclusion Criteria: unconsciousness, not able to consent reanimation, cardiac shock

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Stable CAD, ASA, NSAID<br> | |
| Stable CAD, ASA<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Thromboxane-levels and light-transmission aggregometry in response to arachidonic acid |  | During hospital stay |
Contrast-Enhanced Ultrasound Diagnosis of Acute Appendicitis

Study Overview
=================
Brief Summary
-----------------
This study evaluates the ability of contrast-enhanced ultrasound to improve the diagnosis of acute appendicitis in children compared to conventional ultrasound.

Detailed Description
-----------------
Acute appendicitis is the most common surgical emergency in children. Diagnostic evaluation for possible appendicitis frequently leads to imaging studies. Magnetic resonance imaging (MRI) and computed tomography (CT) are currently the gold-standard techniques for the diagnosis or exclusion of acute appendicitis. However, these methods not always immediately available; may require administration of intravenous contrast material with the potential for allergic reactions and nephrotoxicity; and, in the case of CT, requires the administration of ionizing radiation that is linked to the long-term development of radiation-induced cancers. The current study will evaluate a potentially safer, radiation-free diagnostic method for acute appendicitis, using contrast-enhanced ultrasound to provide a more accurate means of visualizing the appendix than conventional US imaging.

Official Title
-----------------
Contrast-Enhanced Ultrasound Diagnosis of Acute Appendicitis

Conditions
-----------------
Appendicitis Acute

Intervention / Treatment
-----------------
* Drug: Sulfur hexafluoride lipid-type A microspheres


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children who have had a conventional abdominal US study to rule out acute appendicitis and are scheduled for an MRI or CT examination. Exclusion Criteria: Children with serious comorbid conditions, including but not restricted to severe cardiac, pulmonary, renal, or hepatic disease; prior bone marrow or solid organ transplant; cancer; or presence of a ventriculoperitoneal shunt. Children with an allergy to either the active or inactive components of Lumason. Pregnant or nursing patients.

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: IV Contrast-Enhanced US<br>IV sulfur hexafluoride lipid-type A microspheres, 0.03 mL/kg, 2 doses per examination, total dose not to exceed 4.8 mL. Single examination per patient. | Drug: Sulfur hexafluoride lipid-type A microspheres<br>* Contrast-enhanced US imaging of the appendix<br>* Other names: Lumason;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Contrast-enhanced ultrasound diagnosis of acute appendicitis | The efficacy of contrast-enhanced US in improving the diagnosis of acute appendicitis compared to conventional US will be assessed. | One week |
Electrophysiological Reactivity Due to Mobile Phone Radiation

Study Overview
=================
Brief Summary
-----------------
The main objective of this study is to investigate whether radiofrequency electromagnetic radiation, induced by a dialing mobile phone placed on the body, causes a change in electrophysiology.

Detailed Description
-----------------
The aim of this study is to investigate whether placement of a 3G dialing mobile phone causes direct changes in EEG activity compared to the placement of a sham phone. Furthermore, it is investigated whether placement of the mobile phone on the ear or the heart results in different outcomes. The subjects are measured twice: on one of the two days the mobile phone is attached to the ear, the other day to the chest. In this single-blind, cross-over design, assessments in the sham phone conditions are conducted directly preceding and following the mobile phone exposure. During each assessment, EEG activity and radiofrequency radiation are recorded jointly. Delta, theta, alpha, slowbeta, fastbeta, and gamma activity are computed. The association between radiation exposure and the EEG is tested using multilevel random regression analyses with radiation as predictor of main interest.

Official Title
-----------------
Radiation Meter Controlled Electrophysiological Reactivity (EEG and ECG) Due to Mobile Phone Radiation.

Conditions
-----------------
Healthy Subjects

Intervention / Treatment
-----------------
* Radiation: a dialing smartphone will be placed on the chest and the ear


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: female aged between 18 - 30 years Exclusion Criteria: cardiac or brain disorder pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Experimental: Mobile phone radiation<br>Dialing mobile phone placed against the ear/chest for a duration of 15 minutes, before and after 15 minutes sham phone will be placed against the ear/chest. | Radiation: a dialing smartphone will be placed on the chest and the ear<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in EEG and ECG |  | during mobile phone exposure (immediately) |